Adaptimmune (ADAP)

Adaptimmune

The time to redefine the treatment of cancer is now.

About Us

Redefining the treatment of solid tumor cancers.

Adaptimmune is committed to treating the most challenging solid tumors using a proprietary cell therapy platform that harnesses a patient's cells to combat their cancer.

Using a personalized approach that has the potential to radically improve the patient experience.

We use cell therapy, a promising yet complex area of science, to engineer a person’s own cells to fight cancer.

A future where a single infusion could reshape cancer care.

We are a fully integrated company on the verge of a new era. With our first BLA submitted to the FDA, we are aiming to commercialize the  first engineered T-cell therapy in solid tumors to help improve cancer treatment.

SEC Filings

For all investor or media inquiries, visit https://www.adaptimmune.com/contact.

Filing date	Description	Form	Filing Group	View
Oct 23, 2018	UPLOAD	UPLOAD	Other	0000000000-18-033200.pdf 0000000000-18-033200.rtf View HTML
Oct 10, 2018	mendment to a previously filed DRS	DRS/A	Registration Statements	0000950123-18-009813.pdf 0000950123-18-009813.rtf 0000950123-18-009813.xls View HTML
Oct 04, 2018	UPLOAD	UPLOAD	Other	0000000000-18-031306.pdf 0000000000-18-031306.rtf View HTML
Sep 07, 2018	Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy	DRS	Registration Statements	0000950123-18-009342.pdf 0000950123-18-009342.rtf 0000950123-18-009342.xls View HTML

Data provided by Kaleidoscope.

Adaptimmune (ADAP)

Adaptimmune

The time to redefine the treatment of cancer is now.

About Us

Redefining the treatment of solid tumor cancers.

Adaptimmune is committed to treating the most challenging solid tumors using a proprietary cell therapy platform that harnesses a patient's cells to combat their cancer.

Using a personalized approach that has the potential to radically improve the patient experience.

We use cell therapy, a promising yet complex area of science, to engineer a person’s own cells to fight cancer.

A future where a single infusion could reshape cancer care.

We are a fully integrated company on the verge of a new era. With our first BLA submitted to the FDA, we are aiming to commercialize the  first engineered T-cell therapy in solid tumors to help improve cancer treatment.

Adaptimmune

Our fight with cancer is personal.

The time to redefine the treatment of cancer is now.

Redefining the treatment of solid tumor cancers.

Using a personalized approach that has the potential to radically improve the patient experience.

A future where a single infusion could reshape cancer care.

SEC Filings

For all investor or media inquiries, visit https://www.adaptimmune.com/contact.

Adaptimmune

Our fight with cancer is personal.

The time to redefine the treatment of cancer is now.

Redefining the treatment of solid tumor cancers.

Using a personalized approach that has the potential to radically improve the patient experience.

A future where a single infusion could reshape cancer care.